April 18, 2018 / 9:09 PM / 5 months ago

BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

April 18 (Reuters) - China NT Pharma Group Co Ltd:

* PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®

* PFENEX INC - PFENEX RECEIVED A PAYMENT OF $2.5 MILLION UPON SIGNING OF AGREEMENT

* PFENEX INC - PFENEX MAY BE ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS OF UP TO $22.5 MILLION BASED ON ACHIEVEMENT OF DEVELOPMENT, SALES-RELATED MILESTONES

* PFENEX INC - PFENEX MAY ALSO BE ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON NET PRODUCT SALES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below